Meeting
2020 ASCO Virtual Scientific Program
Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.
Authors
Andrew David Zelenetz
Memorial Sloan Kettering Cancer Center, New York, NY
Andrew David Zelenetz , Nishitha Reddy , Deepa Jagadeesh , Anastasios Stathis , Huda S. Salman , Jacob D. Soumerai , Vaishalee Padgaonkar Kenkre , Adam Steven Asch , Judith Llorin-Sangalang , Joanne Li , Igor Gorbatchevsky , John M. Pagel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02914938
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8016)
DOI
10.1200/JCO.2020.38.15_suppl.8016
Abstract #
8016
Poster Bd #
349
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
First Author: Umberto Vitolo
Poster
2021 ASCO Annual Meeting
Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.
First Author: Matthew J. Matasar
Poster
2015 ASCO Annual Meeting
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
First Author: Nathan Hale Fowler
Poster
2014 ASCO Annual Meeting
A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
First Author: Nathan Hale Fowler